Saturday 21 December 2024
Internal Reference Number: FOI_7117
Date Request Received: 11/04/2023 00:00:00
Date Request Replied To: 26/04/2023 00:00:00
This response was sent via: By Email
Request Summary: Asthma
Request Category: Companies
| Question Number 1: How many patients have been treated (for any condition) in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
| Answer To Question 1: Dupilumab 18 patients Omalizumab 22 patients None of the other drugs are used at Salisbury Foundation Trust | |
| Question Number 2: Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups: • Age 6 - 11 • Age 12 - 17 • Age 18 and above | |
| Answer To Question 2: All patients are aged 18 and over, no patients in lower age group. | |
| Question Number 3: How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with: • Dupilumab • Omalizumab | |
| Answer To Question 3: • Dupilumab not used • Omalizumab 40 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
